{"entity":"regeneron-pharmaceuticals","id":"ent_regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","wikidata":"Q7308054","page":"https://asof.is/record/regeneron-pharmaceuticals","summary":"Regeneron Pharmaceuticals is an American pharmaceutical company, headquartered in Tarrytown. Its CEO is Leonard S. Schleifer, since 1988. It reported revenue of $14.34B for the period ended December 31, 2025.","title":"Regeneron Pharmaceuticals: CEO Leonard S. Schleifer","key_facts":[{"label":"CEO","value":"Leonard S. Schleifer","note":"since 1988","claim":"clm_31DC6D4DC56C"},{"label":"CFO","value":"Christopher Fenimore","claim":"clm_0D057E1B2379"},{"label":"Headquarters","value":"Tarrytown","claim":"clm_4EBDB058F389"},{"label":"Revenue","value":"$14.34B","recorded":"14,342,900,000 United States dollar","note":"to 2025-12-31","claim":"clm_E5421E95D3E6"},{"label":"Ticker","value":"REGN · Nasdaq","claim":"clm_CE8DC6176B9E"}],"faq":[{"question":"Who is the CEO of Regeneron Pharmaceuticals?","answer":"Leonard S. Schleifer, since 1988, as the AsOf record states with its sources."},{"question":"Where is Regeneron Pharmaceuticals headquartered?","answer":"Tarrytown."},{"question":"What is Regeneron Pharmaceuticals's revenue?","answer":"$14.34B for the period ended December 31, 2025."}],"as_of":"2026-11-09","known_by":null,"since":null,"fact_pages":[{"predicate":"ceo","page":"https://asof.is/record/regeneron-pharmaceuticals/ceo","md":"https://asof.is/record/regeneron-pharmaceuticals/ceo.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/ceo"},{"predicate":"cfo","page":"https://asof.is/record/regeneron-pharmaceuticals/cfo","md":"https://asof.is/record/regeneron-pharmaceuticals/cfo.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/regeneron-pharmaceuticals/headquarters","md":"https://asof.is/record/regeneron-pharmaceuticals/headquarters.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/regeneron-pharmaceuticals/revenue","md":"https://asof.is/record/regeneron-pharmaceuticals/revenue.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/revenue"},{"predicate":"net_income","page":"https://asof.is/record/regeneron-pharmaceuticals/net_income","md":"https://asof.is/record/regeneron-pharmaceuticals/net_income.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/regeneron-pharmaceuticals/operating_income","md":"https://asof.is/record/regeneron-pharmaceuticals/operating_income.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/regeneron-pharmaceuticals/quarterly_revenue","md":"https://asof.is/record/regeneron-pharmaceuticals/quarterly_revenue.md","json":"https://asof.is/v1/entities/regeneron-pharmaceuticals/quarterly_revenue"}],"products":[],"coverage":{"entity":"regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","kind":"organization","sources":[{"source":"wikidata","item":"Q7308054","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":872589,"ticker":"REGN","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":514,"open":22,"retracted":0,"first":"1988-01-01","predicates":{"revenue":{"claims":18,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":53,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":53,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":53,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":72,"open":1,"kind":"fact"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"total_assets":{"claims":67,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":53,"open":1,"kind":"fact"},"research_and_development":{"claims":18,"open":1,"kind":"fact"},"net_income":{"claims":18,"open":1,"kind":"fact"},"total_equity":{"claims":72,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"shares_outstanding":{"claims":9,"open":1,"kind":"fact"},"operating_income":{"claims":18,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"ceo":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":514,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_630C3A822A55","predicate":"agreement","value":"Sanofi","valid_from":"2026-10-01","valid_to":null,"published":"2026-10-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals agreement: Sanofi\", as of 2026-10-01. Claim clm_630C3A822A55, https://asof.is/claim/clm_630C3A822A55, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm.","url":"https://asof.is/claim/clm_630C3A822A55","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2026-10-06T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS,","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm"}},{"id":"clm_5EBA4C72A92F","predicate":"cash_and_equivalents","value":"3,659,100,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,659,100,000 United States dollar\", as of 2026-09-30. Claim clm_5EBA4C72A92F, https://asof.is/claim/clm_5EBA4C72A92F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_5EBA4C72A92F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_31DC6D4DC56C","predicate":"ceo","value":"Leonard S. Schleifer","valid_from":"1988-01-01","valid_to":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ceo: Leonard S. Schleifer\", as of 1988-01-01. Claim clm_31DC6D4DC56C, https://asof.is/claim/clm_31DC6D4DC56C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_31DC6D4DC56C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-04-24T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-08","quote":"Leonard S. Schleifer, M.D., Ph.D., 73, founded the Company in 1988 and has been a director and its President and Chief Executive Officer since its inception.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"id":"clm_0D057E1B2379","predicate":"cfo","value":"Christopher Fenimore","valid_from":"2024-02-01","valid_to":null,"published":"2026-04-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cfo: Christopher Fenimore\", as of 2024-02-01. Claim clm_0D057E1B2379, https://asof.is/claim/clm_0D057E1B2379, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm.","url":"https://asof.is/claim/clm_0D057E1B2379","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm","tier":"primary","publisher":"SEC EDGAR DEF 14A","published_at":"2026-04-24T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Effective February 2024, the board appointed Christopher Fenimore to succeed Robert E. Landry as the Company’s Chief Financial Officer upon Mr. Landry’s retirement.","url":"https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm"}},{"id":"clm_0D4E584017A3","predicate":"cik","value":"0000872589","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cik: 0000872589\", undated. Claim clm_0D4E584017A3, https://asof.is/claim/clm_0D4E584017A3, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0D4E584017A3","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2BC841F0E994","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals fiscal year end: 12-31\", undated. Claim clm_2BC841F0E994, https://asof.is/claim/clm_2BC841F0E994, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2BC841F0E994","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4EBDB058F389","predicate":"headquarters","value":"Tarrytown","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals headquarters: Tarrytown\", undated. Claim clm_4EBDB058F389, https://asof.is/claim/clm_4EBDB058F389, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_4EBDB058F389","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_60E05C2B8B5C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals listed on: Nasdaq\", undated. Claim clm_60E05C2B8B5C, https://asof.is/claim/clm_60E05C2B8B5C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_60E05C2B8B5C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7514724ED5E9","predicate":"net_income","value":"4,504,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,504,900,000 United States dollar\", as of 2025-12-31. Claim clm_7514724ED5E9, https://asof.is/claim/clm_7514724ED5E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_7514724ED5E9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-04"}},{"id":"clm_1B456AFB0CC5","predicate":"operating_income","value":"3,577,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,577,900,000 United States dollar\", as of 2025-12-31. Claim clm_1B456AFB0CC5, https://asof.is/claim/clm_1B456AFB0CC5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1B456AFB0CC5","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-04"}},{"id":"clm_DEF587D6916A","predicate":"quarterly_net_income","value":"1,948,700,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar\", as of 2026-09-30. Claim clm_DEF587D6916A, https://asof.is/claim/clm_DEF587D6916A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_DEF587D6916A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_4585DB96888D","predicate":"quarterly_operating_income","value":"2,048,200,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 2,048,200,000 United States dollar\", as of 2026-09-30. Claim clm_4585DB96888D, https://asof.is/claim/clm_4585DB96888D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4585DB96888D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_4D8C13296D0A","predicate":"quarterly_research_and_development","value":"1,794,700,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,794,700,000 United States dollar\", as of 2026-09-30. Claim clm_4D8C13296D0A, https://asof.is/claim/clm_4D8C13296D0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4D8C13296D0A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_15BDC7B1496E","predicate":"quarterly_revenue","value":"5,115,800,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 5,115,800,000 United States dollar\", as of 2026-09-30. Claim clm_15BDC7B1496E, https://asof.is/claim/clm_15BDC7B1496E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_15BDC7B1496E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_0230630DE966","predicate":"registrant_name","value":"REGENERON PHARMACEUTICALS, INC.","valid_from":"1995-07-26","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals registrant name: REGENERON PHARMACEUTICALS, INC.\", as of 1995-07-26. Claim clm_0230630DE966, https://asof.is/claim/clm_0230630DE966, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_0230630DE966","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_1819F20C7CC4","predicate":"research_and_development","value":"5,850,200,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,850,200,000 United States dollar\", as of 2025-12-31. Claim clm_1819F20C7CC4, https://asof.is/claim/clm_1819F20C7CC4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1819F20C7CC4","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-04"}},{"id":"clm_E5421E95D3E6","predicate":"revenue","value":"14,342,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,342,900,000 United States dollar\", as of 2025-12-31. Claim clm_E5421E95D3E6, https://asof.is/claim/clm_E5421E95D3E6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_E5421E95D3E6","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-04"}},{"id":"clm_24C3500A1DEF","predicate":"shares_outstanding","value":"93,955,110 shares","valid_from":"2012-07-13","valid_to":null,"published":"2012-07-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals shares outstanding: 93,955,110 shares\", as of 2012-07-13. Claim clm_24C3500A1DEF, https://asof.is/claim/clm_24C3500A1DEF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm.","url":"https://asof.is/claim/clm_24C3500A1DEF","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000120677412003062/0001206774-12-003062-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-07-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-07-25"}},{"id":"clm_BAC78AB8CD88","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_BAC78AB8CD88, https://asof.is/claim/clm_BAC78AB8CD88, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_BAC78AB8CD88","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2EE7611EC44C","predicate":"state_of_incorporation","value":"NY","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals state of incorporation: NY\", undated. Claim clm_2EE7611EC44C, https://asof.is/claim/clm_2EE7611EC44C, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_2EE7611EC44C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_CE8DC6176B9E","predicate":"ticker","value":"REGN","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals ticker: REGN\", undated. Claim clm_CE8DC6176B9E, https://asof.is/claim/clm_CE8DC6176B9E, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589.","url":"https://asof.is/claim/clm_CE8DC6176B9E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000872589","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F46BE3EF6472","predicate":"total_assets","value":"44,405,200,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 44,405,200,000 United States dollar\", as of 2026-09-30. Claim clm_F46BE3EF6472, https://asof.is/claim/clm_F46BE3EF6472, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_F46BE3EF6472","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_24A29A7153C0","predicate":"total_equity","value":"33,498,500,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 33,498,500,000 United States dollar\", as of 2026-09-30. Claim clm_24A29A7153C0, https://asof.is/claim/clm_24A29A7153C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_24A29A7153C0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}